Eyeing Early Chronic Disease Detection Through AI-Based Retinal Scans

 
• By David Wild
  
Generate a summary of this article
Listen to this article
Beta

South Korean start-up Mediwhale is using AI-guided retinal scans to predict the risk of eye, cardiovascular and kidney diseases. The company has moved ahead of a small pack of competitors and gained regulatory approval and market access in eight territories through a focus on gathering strong evidence to support algorithms.

Primary Care Physicians Could Soon Use Retinal Images To Detect Systemic Diseases • Source: Shutterstock

It has been the stuff of science fiction for years: a digital scanner screens a person for minute physiological changes, right in the comfort of their home. The device instantaneously detects a disease at its earliest stage, or even before it appears, thus fending off ill health. Now, a body of research and advances in artificial intelligence are bringing that vision closer to reality, with retinal scanning algorithms that can predict the risk of ophthalmic, cardiovascular, and renal diseases.

“The eye is the only organ that shows blood vessels directly in a non-invasive way,” Kevin Choi, co-founder and CEO...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

SpotifyApple PodcastsWebsite

More from Global Vision

Bristol Myers Squibb ASPIREs For Access In LMICs

BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.

This is a test

 
• By Eleanor Malone

Just running through to check Confluence instructions make sense

H2 Investment Life Sciences Uptick Anticipated But Markets Remain Enduringly Cautious

 
• By Ashley Yeo

Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.

WIAT Global: Addressing Inequalities And Following The CAR-T Journey After Treatment

 
• By Anabel Costa-Ferreira

The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 
• By Edwin Elmhirst and Lucie Ellis-Taitt

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.